Eva-Lotta Allan is an experienced biotechnology deal-maker with over 25 years of business development experience from the biotechnology and life science industry in both private and public companies. She has significant operational and investor relations expertise. Ms Allan is Chief Business Officer at Immunocore, an immune-oncology company specializing in the development of soluble T cell receptor based drugs. Immunocore secured Europe’s largest private life sciences financing in July 2015. She was previously at Ablynx NV, where Ms Allan served as Chief Business Officer for close to seven years and brought in multiple strategic partnerships. She is on the board of the Bioindustry Organisation (BIA) in the UK and has served as a Non-Executive Director of Isconova AB. Prior to Ablynx, Ms Allan served as Senior Director of Business Development and Site Operations (Europe) at Vertex Pharmaceuticals where she was also a Director of the Board of Vertex Europe. Ms Allan received her degree in microbiology from the University of Stockholm. Ms Allan is a Swedish citizen, and resides in the UK.

business development, biotechnology ,investor relations